Urologic Oncology-seminars and Original Investigations最新文献

{"title":"Impact of second-look TURBT on high grade recurrence and intravesical therapy in high-risk non-muscle-invasive bladder cancer: A 20-year experience.","authors":"Yakov Klugman, Nicholas M Cordero, Grace Harrington, Mohammad Khan, Joshua Metherell, Ava Giangrasso, Jordan E Carlson, Rafay Tariq, Mariam Abd-Elhamid, Saffa Rehman, Collin Clark, Zhe Jing, Bradley Webster, Qiang Li, Khurshid A Guru, Ahmed A Hussein","doi":"10.1016/j.urolonc.2026.09.006","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.09.006","url":null,"abstract":"<p><strong>Objective: </strong>To describe our 20-year experience with second look Transurethral Resection of Bladder Tumor (SL-TURBT) for high-risk non muscle invasive bladder cancer (NMIBC), and whether it was associated with better response to adjuvant intravesical therapy (IVT) and prognosis.</p><p><strong>Methods: </strong>Retrospective review of our quality assurance TURBT database between 2000 and 2024. All patients with high risk NMIBC who received IVT were included in the study. SL-TURBT was defined as TURBT within 8 weeks of the initial TURBT or if labelled by the clinician as such. Patients were divided into those who received SL-TURBT vs. those who did not. Patients were followed with cystoscopy and urine cytology every 3 months for the first 2 years, then every 6 months for years 3 to 5, then annually thereafter. Annual upper tract imaging was also performed. Kaplan-Meier method was used to depict high grade recurrence (HGRFS) and progression-free (PFS) survival.</p><p><strong>Results: </strong>Of 853 patients were included in the study, 41% received SL-TURBT. Median time between initial and re-TURBT was 5.9 weeks (IQR 4.0-7.1 weeks). Indications for SL-TURBT included absence of detrusor in specimen (35%), T1 high grade disease (32%), Ta high grade (13%), incomplete resection (16%) and CIS (4%). Patients who received IVT exhibited improved 3 years' HGRFS with SL-TURBT (58% compared to 40% without SL-TURBT, log rank P = 0.008). There was no significant difference in PFS.</p><p><strong>Conclusion: </strong>Patients with high risk NMIBC who received a SL-TURBT prior to IVT exhibited improved HGRFS compared to those who received IVT without SL-TURBT.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonmuscle-invasive bladder cancer after solid organ transplantation: Clinical outcomes and recurrence patterns.","authors":"Taeris Guzman, Sean McSweeney, Can Aydogdu, Gabriela Diaz, Mikayla Baer, Christopher Weight, Nima Almassi, Venkakesh Krishnamurthi, Mohamed Eltemamy, Rebecca Campbell, Mohit Sindhani, Laura Bukavina","doi":"10.1016/j.urolonc.2026.08.020","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.08.020","url":null,"abstract":"<p><strong>Background: </strong>Solid organ transplant recipients face an increased risk of bladder cancer and require lifelong immunosuppression, which may alter the natural history and treatment response of nonmuscle-invasive bladder cancer (NMIBC). Balancing cancer control with allograft preservation complicates clinical decision-making, yet outcome data in this population remain scarce.</p><p><strong>Methods: </strong>A retrospective study of transplant recipients diagnosed with NMIBC post-transplant was conducted. The index date was NMIBC diagnosis. NMIBC recurrence was the primary endpoint, with death before recurrence as a competing event. Recurrence-free survival was estimated using Kaplan-Meier methods, and cumulative incidence of recurrence and competing mortality using the Aalen-Johansen estimator. Cox models evaluated predictors of recurrence.</p><p><strong>Results: </strong>Fifty-nine transplant recipients met inclusion criteria (median age 68 years; 89.8% male), with high-risk disease present in 40/59 (67.8%). High-grade disease was present in 38/59 patients (64.4%), with T1 stage in 20/59 (33.9%) and concomitant carcinoma in situ in 13/59 (22.0%). Over a median follow-up of 37.4 months, 11/59 patients (18.6%) experienced recurrence at a median of 15.1 months, all among those receiving Bacillus Calmette-Guérin (BCG) induction. The 5-year cumulative incidence for recurrence was 20.4%, compared with 40.5% for competing mortality. Progression to advanced disease (≥pT2 and/or nodal involvement) occurred in 3/59 (5.1%) overall, predominantly within the high-grade subcohort. All-cause mortality was 36/59 (61.0%), with a bladder cancer-specific mortality of 5/59 (8.5%). In univariable models, tumor size >3 cm (HR 19.53, P = 0.005) and increasing age (HR 1.10, P = 0.066) were associated with recurrence. Granular information on specific non-BCG intravesical regimens was limited, precluding analysis of comparative efficacy among alternative agents in this population.</p><p><strong>Conclusion: </strong>In this single-institution transplant cohort, competing mortality exceeded recurrence risk. Traditional prognostic factors like tumor size predicted recurrence, yet survival was driven by transplant-related comorbidities. These findings support the use of competing-risk methodologies for accurate outcome estimation and highlight the need for individualized, multidisciplinary management in this complex population.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.","authors":"David-Dan Nguyen, Raj Satkunasivam, Jethro C C Kwong, Bobby Shayegan, Aly-Khan Lalani, Geoffrey T Gotto, Amanda E Hird, Andrea Kokorovic, Melissa J Huynh, Ricardo Rendon, Rodney H Breau, Antonio Finelli, Neil Fleshner, Girish S Kulkarni, Alexandre R Zlotta, Christopher J D Wallis","doi":"10.1016/j.urolonc.2026.09.003","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.09.003","url":null,"abstract":"<p><strong>Background: </strong>There is substantial heterogeneity of outcomes among patients with high-risk localized prostate cancer. The recently published PROTEUS trial saught to enrich for aggressive disease using more restrictive eligibility criteria than the commonly used NCCN high-risk definition. We compared patient distributions and oncologic outcomes after radical prostatectomy using PROTEUS and NCCN high-risk criteria.</p><p><strong>Methods: </strong>We used an institutional radical prostatectomy database to classify patients as high-risk by NCCN criteria (Gleason grade group [GGG] 4-5, clinical T3-T4 disease, or PSA > 20 ng/ml) or PROTEUS criteria (overall GGG ≥ 3 plus GGG5 in ≥1 core, GGG4 in ≥2 cores each with >80% involvement, GGG3+ in ≥6 systematic cores, or GGG3+ in ≥3 systematic cores with PSA ≥ 20 ng/ml). Patient distributions were summarized descriptively. Area under the receiver operating curve (AUC) was compared for oncologic outcomes.</p><p><strong>Results: </strong>Among 358 patients, 62 (17%) met NCCN high-risk criteria and 44 (12%) met PROTEUS criteria. Overall, 38 patients met both definitions, 24 met NCCN criteria only, and 6 met PROTEUS criteria only. There were no statistically significant differences in predicting extra-prostatic extension (NCCN 0.56, 95% Confidence interval [CI] 0.52-0.60; PROTEUS 0.56, 95% CI 0.53-0.60; P = 0.96), positive surgical margins (NCCN 0.54, 95% CI 0.49-0.58; PROTEUS 0.52, 95% CI 0.49-0.56; P = 0.45), and PSA > 0.2 at 12 months postoperatively (NCCN 0.59, 95% CI 0.49-0.69; PROTEUS 0.64, 95% CI 0.54-0.75; P = 0.32).</p><p><strong>Conclusion: </strong>PROTEUS criteria, which may be cumbersome in clinical practice, identified a smaller, overlapping, but nonidentical high-risk population compared with NCCN criteria. There were no statistically significant differences in postprostatectomy oncologic outcomes between both definitions. These findings suggest that PROTEUS eligibility criteria represent a more restrictive trial-enrichment definition but may not meaningfully improve discrimination of adverse outcomes relative to standard NCCN high-risk classification.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sociodemographic barriers to receiving adjuvant systemic therapy after nephrectomy for renal cell carcinoma.","authors":"Maximilian Filzmayer, Michele Petix, Leonardo Quarta, Filippo Orlandi, Jordan A Goyal, Luca Carmignani, Alberto Briganti, Salvatore Micali, Shahrokh F Shariat, Mike Wenzel, Yasmine Heß-Busch, Clara Humke, Fred Saad, Felix K-H Chun, Pierre I Karakiewicz","doi":"10.1016/j.urolonc.2026.09.002","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.09.002","url":null,"abstract":"<p><strong>Background: </strong>It is unknown whether sociodemographic barriers affect the use of adjuvant systemic therapy after nephrectomy among eligible renal cell carcinoma patients.</p><p><strong>Methods: </strong>Within Surveillance, Epidemiology, and End Results database, we identified renal cell carcinoma patients eligible for adjuvant systemic therapy after nephrectomy between 2018 and 2022. Multivariable logistic regression models assessed associations between age, marital status, race/ethnicity, and adjuvant systemic therapy use.</p><p><strong>Results: </strong>Of 6,497 eligible patients, 1,163 patients (17.9%) received adjuvant systemic therapy. Treatment rates were lower in patients aged ≥65 years (14.9% vs. 21.2%, odds ratio [OR] 0.60, 95% confidence interval [CI]: 0.52-0.68, P < 0.001), unmarried individuals (15.9% vs. 19.0%, OR 0.75, 95% CI: 0.65-0.87, P < 0.001), and non-Caucasian patients (16.3% vs. 18.7%, OR 0.75, 95% CI: 0.65-0.87, P < 0.001), even after multivariable adjustment for other patient and tumor characteristics. Combined assessment of these 3 sociodemographic characteristics demonstrated a stepwise decrease in treatment rates, that were lowest in ≥65-year-old unmarried non-Caucasians (10.4%, OR 0.29, 95% CI: 0.19-0.41, P < 0.001) and highest in <65-year-old married Caucasians (24.2%, reference).</p><p><strong>Conclusions: </strong>Despite guideline endorsement, only a minority of eligible renal cell carcinoma patients receive adjuvant systemic therapy after nephrectomy. Older age, unmarried status, and non-Caucasian race/ethnicity were independently associated with lower adjuvant systemic therapy receipt. The combination of these established sociodemographic barriers identified the patient subgroup with the lowest likelihood of receiving adjuvant systemic therapy. Efforts aimed at reducing disparities and close gaps in the implementation of guideline-recommended adjuvant systemic therapy use should therefore focus on individuals with this sociodemographic profile.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition\" Volume 35, Issue 10, October 2017, Pages 593-599.","authors":"Andrew M Hau, Manando Nakasaki, Kazufumi Nakashima, Goutam Krish, Donna E Hansel","doi":"10.1016/j.urolonc.2026.09.001","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.09.001","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Trans-perineal prostate biopsy-prognostic factors for \"no prostate tissue\" in biopsy cores: Beyond local anesthesia.","authors":"Erdem Öztürk, İsa Dağlı","doi":"10.1016/j.urolonc.2026.09.005","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.09.005","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Featured SUO Fellow: Steven Monda, MD, MSCI.","authors":"Steven Monda","doi":"10.1016/j.urolonc.2026.09.017","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.09.017","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative enfortumab vedotin-pembrolizumab, gemcitabine-cisplatin-durvalumab, and dose-dense MVAC in cisplatin-eligible muscle-invasive bladder cancer: A benefit-risk Bayesian network meta-analysis.","authors":"José Daniel Subiela, Daniel A González-Padilla, Pietro Scilipoti, Aleksander Slusarczyk, Renate Pichler, Félix Guerrero-Ramos, Alberto Artiles-Medina, Jorge Caño-Velasco, Júlia Aumatell, Wojciech Krajewski, Laura S Mertens, Jeremy Yuen-Chun Teoh, Roberto Contieri, Brigida Anna Maiorano, Francesco Claps, Francesco Del Giudice, David D'Andrea, Pablo Gajate, Patricia Guerrero, Andrea Gallioli, Felipe Villacampa, Eduardo Albers Acosta, Fernando Lozano, Albert Carrion, Luca Afferi, Luis Crespo, Gautier Marcq, Francesco Soria, Marco Moschini, Elisabeth Grobet-Jeandin, Simone Albisinni, Mario Alvarez-Maestro, Luis San-José Manso, Victoria Gomez Dos Santos, Morgan Roupret, Francisco Javier Burgos Revilla, Benjamin Pradere, Oscar Buisan","doi":"10.1016/j.urolonc.2026.09.007","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.09.007","url":null,"abstract":"<p><p>To compare the efficacy and safety of three perioperative regimens for cisplatin-eligible muscle-invasive bladder cancer (MIBC); enfortumab vedotin plus pembrolizumab (EV + P), gemcitabine-cisplatin plus durvalumab (GC + Durva), and dose-dense MVAC (dd-MVAC), in the absence of head-to-head trials, using a Bayesian network meta-analysis (NMA). A systematic search through March 2026 identified phase III trials comparing perioperative regimens against GC in cisplatin-eligible MIBC. The primary analysis was a Bayesian NMA of event-free survival (EFS), overall survival (OS), and pathological complete response (pCR), with SUCRA rankings; risk of bias used RoB-2. Three trials (EV-304, NIAGARA, VESPER; 2,364 patients) formed a star-shaped network vs. GC, all regimens improved EFS-EV + P (Hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.41-0.70), GC + Durva (0.68, 0.56-0.82), dd-MVAC (0.74, 0.55-0.99), and OS, EV + P (0.65, 0.48-0.89), GC + Durva (0.75, 0.60-0.93), dd-MVAC (0.71, 0.52-0.97). EV + P ranked first across all endpoints (SUCRA: EFS 96%, OS 81%, pCR > 99%). Indirect comparisons between experimental regimens were non-significant for survival; only pCR favored EV + P over GC + Durva (odds ratio [OR] 1.7, P < 0.01) and dd-MVAC (OR 2.0, P < 0.01). GC + Durva showed no excess Grade ≥3 toxicity over GC (41% vs. 41%). This NMA provides the first quantitative benefit-risk framework integrating efficacy ranking, toxicity, and subgroup heterogeneity for these regimens. EV + P had the highest probability of improving EFS, OS, and pCR, with GC + Durva ranking second; although directionally consistent with each trial, the magnitude, ranking, and subgroup heterogeneity could not be quantified without indirect synthesis. GC + Durva offered the most favorable benefit-risk profile. Prospective head-to-head trials remain an unmet need.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and internal validation of machine-learning models to predict adverse pathological features in upper tract urothelial carcinoma.","authors":"Philipp Korn, Maximilian Pallauf, Soum Lokeshwar, Giacomo Musso, Zhenje Wu, Linhui Wang, Alex Kutikov, Randall Lee, Francesco Ditonno, Alessandro Veccia, Riccardo Bertolo, Alessandro Antonelli, Lin Lin, Vitaly Margulis, Alireza Ghoreifi, Hooman Ebrahimi, Hooman Djaladat, Hidefumi Kinoshita, Takashi Yoshida, Gabriele Tuderti, Flavia Proietti, Giuseppe Simone, Andrea Mari, Luca Lambertini, Andrea Minervini, Marco Tozzi, Matteo Ferro, Roberto Contieri, Sisto Perdona, Daniele Amparore, Gabriele Bignante, Francesco Porpiglia, Omri Falik Nativ, Mark L Gonzalgo, Alfonso Santangelo, Carlo Silvani, Alex Stephens, Firas Abdollah, Melinda Fu, Saum Ghodoussipour, Alec Zhu, Reza Mehrazin, Daniel A Sidhom, Chandru P Sundaram, Takashi Matsumoto, Masaki Shiota, Alireza Dehghanmanshadi, Soroush Rais-Bahrami, Karim Daher, Ithar H Derweesh, Riccardo Autorino, Nirmish Singla","doi":"10.1016/j.urolonc.2026.08.017","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.08.017","url":null,"abstract":"<p><strong>Background: </strong>Accurate preoperative staging and identification of adverse pathological features in upper tract urothelial carcinoma (UTUC) remain contemporary challenges. We aimed to develop and internally validate machine-learning (ML) models to predict muscle-invasive (≥pT2) and lymph node positive (pN+) disease using preoperative variables.</p><p><strong>Material and methods: </strong>We analyzed a large, multi-institutional registry of patients treated surgically for clinically nonmetastatic UTUC (ROBUUST 3.0). We separately identified patients with ≥pT2 stage and pN+ stage at surgery. Predictors were selected a priori based on clinical relevance, and missing data were imputed using Hyperimpute. Five classifiers (elastic net logistic regression, random forest, LightGBM, support vector machine with radial-basis-function kernel and a stacking ensemble) were trained using an 80/20 stratified train-test split. Discrimination (measured by area under the curve (AUC)), calibration and Brier score were assessed in the independent test cohort.</p><p><strong>Results: </strong>We identified 3,179 patients with ≥pT2 stage (636 designated as the test cohort) and 1493 patients with pN+ disease (299 designated as the test cohort). In the test cohort, discrimination was moderate and comparable across models. For ≥pT2 prediction, AUC ranged from 0.73 to 0.74 (best model: stacking, AUC 0.74, 95% confidence interval [CI]: 0.70-0.78, and Brier 0.21). For pN+, AUC ranged from 0.73 to 0.75 (best model: stacking, AUC 0.75, 95% CI 0.69-0.81, and Brier 0.18). Established clinical predictors, particularly biopsy grade and clinical staging parameters dominated risk estimation. Limitations include retrospective design and lack of external validation.</p><p><strong>Conclusions and clinical implications: </strong>ML models using preoperative variables achieved moderate discrimination for predicting adverse pathological features in UTUC. External validation and prospective assessment of clinical utility are necessary before informing preoperative patient selection.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of the EORTC and CUETO risk prediction models in contemporary patients undergoing transurethral resection of bladder tumor with blue light cystoscopy.","authors":"Agustin Perez-Londoño, Sumedh Kaul, Aaron Fleishman, Badrinath Konety, Kamal Pohar, Jeffrey M Holzbeierlein, John Taylor, Max Kates, Brian Willard, Jennifer M Taylor, Joseph C Liao, Hristos Z Kaimakliotis, Sima P Porten, Gary D Steinberg, Mark D Tyson, Yair Lotan, Siamak Daneshmand, Boris Gershman","doi":"10.1016/j.urolonc.2026.08.005","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.08.005","url":null,"abstract":"<p><strong>Background and objective: </strong>The European Organization for Research and Treatment of Cancer (EORTC) and the Club Urológico Español de Tratamiento Oncológico (CUETO) risk prediction models are established tools for predicting recurrence and progression in non-muscle invasive bladder cancer. However, their performance in patients undergoing TURBT with blue light cystoscopy (BLC-TURBT), which reduces disease recurrence, has not been examined. We, therefore, evaluated the performance of these models in a contemporary cohort of patients undergoing BLC-TURBT.</p><p><strong>Methods: </strong>We identified patients aged 18 to 89 years in the multi-institutional Blue Light Cystoscopy with Cysview Registry who underwent BLC-TURBT between 2014 and 2023. We predicted disease recurrence- and progression-free survival estimates using the EORTC and CUETO models, and estimated observed recurrence-free (RFS) and progression-free (PFS) survival using the Kaplan-Meier method.</p><p><strong>Results: </strong>A total of 899 patients were included. Tumor stage was Ta in 658 (73%) and T1 in 241 (27%) patients. EORTC risk score groups were associated with a statistically significant difference in RFS, whereas CUETO risk score groups were not. Observed RFS and PFS estimates were generally higher than that predicted by the EORTC risk score, while observed RFS and PFS were inconsistently related to that predicted by the CUETO risk score. The c-statistics for RFS and PFS by risk score group were 0.59 and 0.67 for EORTC, and 0.53 and 0.72 for CUETO, respectively.</p><p><strong>Conclusions: </strong>In a contemporary cohort of patients undergoing BLC-TURBT, the EORTC and CUETO models demonstrated poor performance in predicting RFS and PFS. These results underscore the need for development of more accurate predictive models to guide the risk-adapted management of patients undergoing BLC-TURBT.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}